Genotyping, Other Clinical Variables May Predict Everolimus Treatment Effects

the Cancer Therapy Advisor take:

The PI3KCA gene polymorphism, lactate dehydrogenase (LDH), and histologic grade can predict the effects of everolimus treatment, while corrected calcium level and a PIK3CA gene variant may be independent prognostic factors in patients with metastatic renal cell carcinoma, a new study published online in the journal Annals of Oncology has shown.

For the prospective, single-arm, phase II trial, researchers sought to identify predictive and prognostic factors in patients with metastatic renal cell carcinoma treated with everolimus 10mg daily. Specifically, they evaluated potential biomarkers of the PI3K/AKT/mTOR pathway.

Results showed that histological grade G1/2 (HR = 2.68; 95% CI: 1.29-5.58; P = 0.0082), increased LDH before treatment (HR = 2.55; 95% CI: 1.30-4.99; P = 0.0064), and the PIK3CA gene variant rs6443624 (HR = 2.08; 95% CI: 1.11-3.89; P = 0.0254) were adverse independent predictors for everolimus treatment.

Researchers also found that elevated corrected calcium level (HR = 4.17; 95% CI: 1.66-10.51; P = 0.0024) and the PIK3CA gene variant rs6443624 (HR = 1.97; 95% CI: 1.02-3.79; P = 0.0421) may be independent prognostic factors.

The authors note that further prospective studies are warranted to confirm and validate these findings.